US Polycystic Ovary Syndrome Treatment Market: Segment Snapshot and Table of Content (2016-2024)

Prevalence of endocrine diseases in the US is on a rise as the country’s urban residents continue to bear the brunt of their sedentary lifestyles. Rising incidence of endometriosis, unexplained infertility and polycystic ovarian syndrome (PCOS) continues to alarm public health authorities across the US. Measures undertaken by non-profit organizations and US health regulatory bodies are promoting the awareness of PCOS treatments. Also, therapies for diseases associated with PCOS are being developed to bear out the unmet clinical needs of people suffering from such complications. Despite this, the demand for PCOS treatment continues to incur a sluggish growth across the US. Persistence Market Research’s recent publication estimates that the US$ 230 Mn PCOS treatment market in the US will exhibit a moderate value CAGR of 3.9% to reach US$ 313.2 Mn by the end of 2024.

Titled as “Polycystic Ovary Syndrome Treatment Market: US Industry Analysis and Forecast, 2016-2024,” the report projects that in 2016, more than US$ 66 Mn worth of oral contraceptive drugs were consumed in the US polycystic ovary syndrome treatment market. Through 2024, oral contraceptives will be exhibiting a steady revenue growth at 5.3% CAGR, and will account for nearly one-third share of market value. Besides, the demand for insulin sensitizing agents is expected to close in on number of oral contraceptives consumed in the US PCOS treatment market during this forecast period. Furthermore, growing preference to advanced drugs will also boost the consumption of aromatase inhibitors & SERMs, revenues from which will reach US$ 49 Mn by 2024-end.

Get Full Report @ https://www.persistencemarketresearch.com/market-research/us-polycystic-ovarian-syndrome-treatment-market.asp

More than 47% of US polycystic ovary syndrome treatment market will be accounted by drug sales through hospital pharmacies. With hospitals as the largest distribution channel, nearly US$ 150 Mn worth of PCOS drugs will be sold through these pharmacies. Meanwhile, PCOS drug sales through e-commerce platforms are projected to showcase a value CAGR of 4.6%, higher than that of hospital pharmacies and other distribution channels such as fertility clinics, drug stores and over-the-top counters.

The global US Polycystic Ovary Syndrome Treatment Market is segmented on the basis of drug class, product, type and region.

Increasing healthcare expenditure is being witnessed in many developed countries worldwide including the U.S. This indicates that people have become more health conscious and hence are increasingly inclined towards enhanced treatment options for various ailments. This is one among the primary factors driving the growth of the insulin sensitizing agents drug class segment. Polycystic ovarian syndrome associated diseases, especially obesity and insulin insensitivity are increasing; however, the exact cause of polycystic ovarian syndrome is so far unknown and there are no drugs approved for direct treatment of polycystic ovarian syndrome. However, associated conditions can be controlled with drugs such as insulin sensitizing agents. Thus, an increasing need for associated disease management is expected to contribute significantly to the growth of the insulin sensitizing agents drug class segment. Also, rising R&D expenditure and an introduction of novel drugs is expected to fuel market growth of the insulin sensitizing agents drug class segment over the forecast period. Companies in the U.S are currently focusing on research and development of novel drugs to enable better management of associated diseases such as obesity, insulin sensitivity, hirsutism etc.

Besides, polycystic ovarian syndrome drugs manufacturers are focusing on the commercial distribution of medicines through retail pharmacies and online portals. Online portals widely distribute polycystic ovarian syndrome drugs with or without prescription. Moreover, consumers can avail discounts on bulk purchase of medicines through online portals. Hence, easy availability and discounts contribute significantly to increasing adoption of insulin sensitizing agents. The development of the insulin sensitizing agents drug class segment is also attributed to increasing disposable income and improving healthcare facilities in the U.S. The growth of the segment is further credited to several awareness programs initiated by the U.S government.

Drugs used for polycystic ovarian syndrome are not covered in most coverage policies or health insurance. The cost of few drugs are comparatively high in the U.S. Thus, reduction in the cost of branded drugs would help in the adoption of polycystic ovarian syndrome drugs across the globe. Currently, only Metformin, an insulin sensitizing agent has been included in the list of reimbursed medicines. Taking into consideration the high cost of insulin sensitizing agents in various countries such as the U.S., polycystic ovarian syndrome drugs could be covered under reimbursement policies, which would help propel the growth of the insulin sensitizing agents drug class segment.

Request A Sample Report @ https://www.persistencemarketresearch.com/samples/14317

Summary of Table of Content
1.Executive Summary
2.Market Introduction
3.Market Analysis Scenario
4.Market Dynamics
5.U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Drug Class
6.U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Distribution Channel
7.Competition Landscape
8. Assumptions and Acronyms Used
9. Research Methodology

Request to Browse Full Table of Content, figure and Tables @ https://www.persistencemarketresearch.com/market-research/us-polycystic-ovarian-syndrome-treatment-market/toc

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.